The Value of Microglassification
Over half of all current antibody therapeutics on the market are administered through an intravenous (IV) infusion in a hospital setting. Microglassification™ suspensions (MG Suspensions) offer an alternative approach to this conventional delivery of biologics. Microglassification™ allows formulation as suspensions of solid particles.
Value to Patients
Subcutaneous injections give patients the option to self-administer their medication in the privacy of their home rather than spending hours in a clinic. This is a dramatic quality of life improvement, letting them continue their daily life uninterrupted.
Value to Payers
Eliminating or reducing the need for IV infusions as well as diminishing the materials and administration time required of healthcare professionals will significantly help lower costs, increase resource savings, and improve treatment delivery. The potential economic impact along with patient compliance of self-administered subcutaneous injection will help bring considerable economic and humanistic Value to Payers.
Value to Pharma
MG Suspensions give pharma companies a value-add advantage by offering convenience to patients and extending their product life cycle. Additionally, since Microglassification™ is a platform approach, it can decrease the development time required to get new molecules into the clinic.
Advantages to Microglassification Technology
Partner with Us!
Our team is developing highly concentrated suspensions of biologics that enable subcutaneous delivery. This will enable greater patient comfort, compliance, and convience, while also decreasing costs. Lindy Biosciences is seeking partnerships with companies in the biotechnology and pharmaceutical sectors to join us in developing this technology.